It's not "no shot," though. It's other existing, widely available forms of pre-exposure prophylaxis.
They're not comparing the new treatment to nothing. They're comparing it to existing treatments.
They're not comparing the new treatment to nothing. They're comparing it to existing treatments.
> The shot was also superior to once-daily Truvada, another Gilead drug that is used for HIV prevention.
That's good news. As I understand it the existing treatments were already very good. And these injections are only once per year.
Probably quite a bit. The trial used the same dose of lenacapavir as what's used for maintenance in HIV patients; it's quite possible that less is needed to prevent infection in a healthy patient. Unfortunately, there's really no safe/ethical way for them to test lower doses.